Karl Freydl, DO
Interventional Pain Medicine · Novi, MINPI 1720183353
Payments from drug & device makers
What this record shows
13 manufacturers reported payments, led by Boston Scientific at 57.1% of the total. Reporting peaked in 2023 at $2,260 and has fallen 87.5% since, to $283 in 2025.
Across 55 payments — averaging $83.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Relievant Medsystems, Inc.$970
- Nevro Corp.$351
- Nalu Medical, Inc.$114
- Globus Medical$111
- Vertiflex, Inc.$108
- plus $315 from 7 others
What the payments were for
- Travel & lodging$2,57056%
- Food & beverage$2,01844%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 28 | $2,620 |
| Relievant Medsystems, Inc. | 3 | $970 |
| Nevro Corp. | 5 | $351 |
| Nalu Medical, Inc. | 5 | $114 |
| Globus Medical | 1 | $111 |
| Vertiflex, Inc. | 2 | $108 |
| Abbott | 4 | $83 |
| Painteq LLC | 1 | $77 |
| SPR Therapeutics, Inc | 1 | $55 |
| Stryker | 2 | $48 |
| Averitas Pharma Inc. | 1 | $19 |
| Si-bone, Inc. | 1 | $18 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$1,939
- GENERAL - THERAPIES$133
- Senza Spinal Cord Stimulation System$121
- Omnia$111
- Excelsius - GPS$111
How this compares
$4,589 in reported general payments places this provider in the 65th percentile of 88 interventional pain medicine providers in Michigan.
See all interventional pain medicine providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 74 | $1,335 |
| Gabapentin | 89 | $940 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 36 | $564 |
| Duloxetine Hcl | 28 | $321 |
| Celecoxib | 14 | $261 |
| Methocarbamol | 29 | $213 |
| Oxycodone Hcl | 19 | $210 |
| Pregabalin | 18 | $191 |
| Tramadol Hcl | 32 | $178 |
| Meloxicam | 16 | $24 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Novi
- Leila EttefaghNovi$2K
- Ryan PollinaSaint Clair Shores$144K
- Ariel MajjhooMonroe$124K
- Chad BrummettAnn Arbor$109K
- Anand ThakurClinton Township$102K
- Evan PeskinFlint$72K
- Richard FerroLansing$31K
- John ChatasAnn Arbor$29K
- Bryant IttiaraAllen Park$28K
- Fadi DellyWyandotte$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.